drugset / Trial / NCT06029530

Summary

Participants eligible for the study will be randomized to one of three concentrations of atropine and followed for a month.

Timeline

Start
2024-01-01
Primary completion
2024-08-31
Completion
2024-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atropine Other / unclassified 0.01 % Topical
Comparator Atropine Other / unclassified 0.03 % Topical
Comparator Atropine Other / unclassified 0.05 % Topical

Indications